Coronavirus disease 2019 (COVID-19) pandemic caused infection in a season when influenza is still prevalent. Both viruses have similar transmission characteristics and common clinical manifestations. Influenza has been described to cause respiratory infection with some other respiratory pathogens. However, the information of COVID-19 and influenza coinfection is limited. In this study, we reported our coinfected cases and reviewed the literature. We included all COVID-19 diagnosed patients. All patients with a presumed diagnosis of COVID-19 were routinely screened for influenza. Their thorax radiology was reviewed for COVID-19-influenza differentiation. During the study period, 1103 patients have been diagnosed with COVID-19. Among them, six patients (0.54%) were diagnosed coinfected with influenza. There have been 28 more coinfected patients reported. Laboratory-based

We have read the case report of Kutlu and Metin with great interest. 1 They have reported a patient with psoriasis and Covid-19 treated with hydroxychloroquine and oseltamivir. The patient developed exacerbation of psoriasis at fourth day of this treatment. They suggested that the exacerbation of psoriasis was due to the use of hydroxychloroquine, while they briefly discussed the possibility that Covid-19 disease might trigger the exacerbation of psoriasis. We have recently seen a patient with psoriasis and Covid-19 who may contribute to psoriasis and Covid-19 interaction. A 48-year-old female was admitted with fever, cough, shortness of breath, and exacerbation of psoriatic lesions. She had a diagnosis of psoriasis for 30 years given several systemic and topical drugs: She used acitretin, 30 mg/day, for 5 weeks 3 years ago, and methotrexate (first oral 15 mg/week, 6 weeks, then subcutaneous 25 mg/week, 8 weeks) with folic acid, 1.5 years ago. Her last treatment was topical:

Background: In inflammatory bowel disease (IBD) number of thromboembolic events are increased due to hypercoagulupathy and platelet activation. Increases in mean platelet volume (MPV) can lead to platelet activation, this leads to thromboembolic events and can cause acute coronary syndromes. In IBD patients, QT-dispersion and P-wave dispersion are predictors of ventricular arrhythmias and atrial fibrilation; MPV is accepted as a risk factor for acute coronary syndromes, we aimed at evaluating the correlations of these with the duration of disease, its localization and activity.Methods: The study group consisted of 69 IBD (Ulcerative colitis n: 54, Crohn's Disease n:15) patients and the control group included 38 healthy individuals. Disease activity was evaluated both endoscopically and clinically. Patients with existing cardiac conditions, those using QT prolonging medications and having systemic diseases, anemia and electrolyte imbalances were excluded from the study. QT-dispersion, P-wave dispersion and MPV values of both groups were compared with disease activity, its localization, duration of disease and the antibiotics used.Results: The P-wave dispersion values of the study group were significantly higher than those of the control group. Duration of the disease was not associated with QT-dispersion, and MPV levels. QT-dispersion, P-wave dispersion, MPV and platelet count levels were similar between the active and in mild ulcerative colitis patients. QT-dispersion levels were similar between IBD patients and the control group. No difference was observed between P-wave dispersion, QT-dispersion and MPV values; with regards to disease duration, disease activity, and localization in the study group (p>0.05).Conclusions: P-wave dispersion which is accepted as a risk factor for the development of atrial fibirilation was found to be high in our IBD patients. This demonstrates us that the risk of developing atrial fibrillation may be high in patients with IBD. No significant difference was found in the QT-dispersion, and in the MPV values when compared to the control group.

We have read the study of Yue et al 1 with great interest. They reported influenza coinfection among 307 coronavirus disease 2019 (COVID-19) patients as 57.3%. The study included a period

No abstract